The U.S. sucralfate market offers products that protect ulcers in the esophagus, stomach and small intestine from further damage. Sucralfate aids in ulcer healing by forming a protective covering over the ulcer which helps in preventing further injury to the lining of the digestive tract. The demand for sucralfate is rising owing to increasing incidence of ulcers caused by stress, medication intake and lifestyle changes.
The Global U.S. Sucralfate Market is estimated to be valued at US$ 70.05 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Global U.S. Sucralfate Market Demand are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Allergan plc.
The growing demand for ulcer treatment drugs across the United States is a major factor fueling the growth of the sucralfate market. The increasing number of prescriptions for nonsteroidal anti-inflammatory drugs and other medications that may cause gastrointestinal ulcers has augmented the demand for sucralfate products.
Geographic expansion of key players into new territories and acquisitions & partnerships with regional pharmaceutical players to bolster product access across the US healthcare setup is expected to drive the sucralfate market growth over the forecast period.
Market key trends
One of the key trends witnessed in the US sucralfate market is the introduction of sucralfate in new oral formulations and delivery forms for enhancing patient compliance. Several manufacturers are engaged in developing sucralfate tablets and effervescent granule formulations that ensure improved and faster drug delivery. This is anticipated to positively impact the adoption of sucralfate products among patients and healthcare practitioners.
Porter’s Analysis
Threat of new entrants: High capital requirements and stringent regulations from FDA act as entry barriers.
Bargaining power of buyers: Buyers have medium bargaining power as sucralfate drugs are often substitutes for each other and can easily switch to alternative drugs available.
Bargaining power of suppliers: Suppliers have medium to low bargaining power due to availability of substitute raw materials and active pharmaceutical ingredients.
Threat of new substitutes: Few alternatives exist but they may gain market share in future due to perceived advantages.
Competitive rivalry: Strong as major players compete on basis of price and brand value.
Geographical Regions
The United States accounts for largest share of sucralfate market value currently. High prevalence of gastric ulcers and frequent prescription of sucralfate drugs majorly contribute to this concentration.
Asia Pacific region is expected to be fastest growing for sucralfate market during forecast period. Rising geriatric population, improving access to healthcare facilities and growing medical tourism are key factors fueling the demand. Countries like India, China and Japan are expected to be high potential markets.
Get more insights on this topic: U.S. Sucralfate Market
Comments
0 comment